EU approves first vaccine for common respiratory virus

The European Commission has followed the United States in approving the world’s first vaccine for the Respiratory Syncytial Virus, to be used by adults aged 60 and over, its maker GlaxoSmithKline said Wednesday. “This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time,” GSK’s chief scientific officer Tony